Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four new employees as employment inducements. The options total 238,500 shares with an exercise price of $3.69 per share, matching the closing price on July 31, 2025.
The options will vest over a 4-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) and are subject to continued employment with Akebia.
Akebia Therapeutics (Nasdaq: AKBA), un'azienda biofarmaceutica specializzata nelle malattie renali, ha concesso opzioni su azioni a quattro nuovi dipendenti come incentivo all'assunzione. Le opzioni ammontano a un totale di 238.500 azioni con un prezzo di esercizio di 3,69 $ per azione, corrispondente al prezzo di chiusura del 31 luglio 2025.
Le opzioni matureranno in un periodo di 4 anni, con il 25% che matura dopo il primo anno e il restante 75% che matura trimestralmente successivamente. Queste opzioni, con durata di 10 anni, sono state concesse in conformit脿 alla Regola Nasdaq 5635(c)(4) e sono soggette alla continuazione dell'impiego presso Akebia.
Akebia Therapeutics (Nasdaq: AKBA), una compa帽铆a biofarmac茅utica centrada en enfermedades renales, ha otorgado opciones sobre acciones a cuatro nuevos empleados como incentivos laborales. Las opciones suman un total de 238,500 acciones con un precio de ejercicio de $3.69 por acci贸n, igualando el precio de cierre del 31 de julio de 2025.
Las opciones se consolidar谩n durante un per铆odo de 4 a帽os, con un 25% consolidado tras el primer a帽o y el 75% restante consolidado trimestralmente despu茅s. Estas opciones con un plazo de 10 a帽os fueron otorgadas bajo la Norma Nasdaq 5635(c)(4) y est谩n sujetas a la continuidad del empleo con Akebia.
Akebia Therapeutics (雮橃姢雼�: AKBA)電� 鞁犾灔 歆堩櫂鞐� 欷戩爯鞚� 霊� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雱� 氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 瓿犾毄 鞙犾澑毂呾溂搿� 欤检嫕 鞓奠厴鞚� 攵�鞐枅鞀惦媹雼�. 鞓奠厴鞚赌 齑� 238,500欤�鞚措┌, 頄夓偓臧�瓴╈潃 欤茧嫻 3.69雼煬搿� 2025雲� 7鞗� 31鞚� 膦呹皜鞕� 霃欖澕頃╇媹雼�.
鞓奠厴鞚赌 4雲� 旮瓣皠鞐� 瓯胳硱 氩犾姢韺呺悩氅�, 觳� 頃� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆� 75%電� 攵勱赴氤勲 氩犾姢韺呺惄雼堧嫟. 鞚� 10雲� 毵岅赴 鞓奠厴鞚赌 雮橃姢雼� 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 攵�鞐悩鞐堨溂氅� Akebia鞐愳劀 瓿勳啀 瓿犾毄 欷戩澑 瓴届毎鞐愲 鞙犿毃頃╇媹雼�.
Akebia Therapeutics (Nasdaq : AKBA), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les maladies r茅nales, a accord茅 des options d'achat d'actions 脿 quatre nouveaux employ茅s en tant qu'incitations 脿 l'embauche. Les options totalisent 238 500 actions avec un prix d'exercice de 3,69 $ par action, correspondant au cours de cl么ture du 31 juillet 2025.
Les options seront acquises sur une p茅riode de 4 ans, avec 25 % acquis apr猫s la premi猫re ann茅e et les 75 % restants acquis trimestriellement par la suite. Ces options d'une dur茅e de 10 ans ont 茅t茅 accord茅es conform茅ment 脿 la r猫gle Nasdaq 5635(c)(4) et sont soumises 脿 la poursuite de l'emploi chez Akebia.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen mit Schwerpunkt auf Nierenerkrankungen, hat vier neuen Mitarbeitern als Anreiz zur Einstellung Aktienoptionen gew盲hrt. Die Optionen umfassen insgesamt 238.500 Aktien mit einem Aus眉bungspreis von 3,69 $ pro Aktie, entsprechend dem Schlusskurs vom 31. Juli 2025.
Die Optionen werden 眉ber einen Zeitraum von 4 Jahren erworben, wobei 25 % nach dem ersten Jahr und die restlichen 75 % anschlie脽end viertelj盲hrlich freigegeben werden. Diese Optionen mit einer Laufzeit von 10 Jahren wurden gem盲脽 Nasdaq-Listing-Regel 5635(c)(4) gew盲hrt und unterliegen der fortgesetzten Besch盲ftigung bei Akebia.
- None.
- None.
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia鈥檚 common stock on July 31, 2025. The options were granted as an inducement material to聽each employee聽entering into employment with Akebia.聽The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at聽, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
FAQ
What stock options did Akebia Therapeutics (AKBA) grant to new employees in July 2025?
What is the vesting schedule for Akebia's (AKBA) July 2025 employee stock options?
What is the exercise price for Akebia's (AKBA) July 2025 inducement grants?
Under which rule were Akebia's (AKBA) July 2025 stock options granted?
